-transparent.png){kind=logo}
Levamisole, an anthelminthic agent with immunostimulatory properties, was used in a double-blind, controlled therapeutic trial in rheumatoid arthritis. Patients received either levamisole 100 mg 4 days a week, or placebo, for a period of 4 months. Significant improvement in the treated group, as compared with the control group, was found in the number of tender and swollen joints, grip strength, range of joint motion, sedimentation rate, and C-reactive protein. On double-blind global evaluation by the examining physicians, 9 of 14 patients on levamisole and none of 13 on placebo were considered to have improved. Adverse effects did not differ in frequency between the two groups except for mild alteration in taste, which was more common with levamisole.
L A Runge, and
R S Pinals, and
S H Lourie, and
R H Tomar
January 1980,
Terapevticheskii arkhiv,
L A Runge, and
R S Pinals, and
S H Lourie, and
R H Tomar
January 1980,
Agents and actions. Supplements,
L A Runge, and
R S Pinals, and
S H Lourie, and
R H Tomar
July 1982,
La Clinica terapeutica,
L A Runge, and
R S Pinals, and
S H Lourie, and
R H Tomar
June 1976,
Revue du rhumatisme et des maladies osteo-articulaires,
L A Runge, and
R S Pinals, and
S H Lourie, and
R H Tomar
October 1977,
La Nouvelle presse medicale,
L A Runge, and
R S Pinals, and
S H Lourie, and
R H Tomar
August 1978,
Annals of the rheumatic diseases,
L A Runge, and
R S Pinals, and
S H Lourie, and
R H Tomar
January 1981,
Terapevticheskii arkhiv,
L A Runge, and
R S Pinals, and
S H Lourie, and
R H Tomar
March 1982,
Polskie Archiwum Medycyny Wewnetrznej,
L A Runge, and
R S Pinals, and
S H Lourie, and
R H Tomar
January 1983,
Revue du rhumatisme et des maladies osteo-articulaires,
L A Runge, and
R S Pinals, and
S H Lourie, and
R H Tomar
January 1998,
Scandinavian journal of rheumatology,
